Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 23Terminated 5Recruiting 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1

Conditions

Multiple Myeloma 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Burkitt Lymphoma 6Leukemia, Biphenotypic, Acute 5Recurrence 3Smoldering Multiple Myeloma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, T-Cell 2Lymphoma, Large B-Cell, Diffuse 2Leukemia 2Immunoglobulin Light-chain Amyloidosis 2Hodgkin Disease 2Blastic Plasmacytoid Dendritic Cell Neoplasm 2Renal Insufficiency 1Proteostasis Deficiencies 1Neoplasms, Plasma Cell 1Neoplasms 1Meningioma 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphoma 1Lymphodepleting Chemotherapy 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Hematologic Neoplasms 1Down Syndrome 1Cytokine Release Syndrome 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

venetoclax 21Cyclophosphamide 14Cytarabine 12Azacitidine 8fludarabine 7Dexamethasone 5Daunorubicin 5ruxolitinib 4revumenib 4Trimethoprim, Sulfamethoxazole Drug Combination 4quizartinib 3pirtobrutinib 3gamma-Globulins 3fludarabine phosphate 3blinatumomab 3Tacrolimus 3Rituximab 3Palliative Care 3Inotuzumab Ozogamicin 3Granulocyte Colony-Stimulating Factor 3Decitabine 3Ciprofloxacin 3Blood Specimen Collection 3zanubrutinib 2ponatinib 2pembrolizumab 2ibrutinib 2aldesleukin 2acalabrutinib 2Watchful Waiting 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Leukemia × Calcium Dobesilate × Clear all
NCT04747912 2026-06-05

Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)

University of Chicago

Phase 2 Recruiting
25 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05645718 2026-05-19

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
27 enrolled
Other hematologic neoplasm

Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡